CGON Relative Valuation
CGON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CGON is overvalued; if below, it's undervalued.
Historical Valuation
CG Oncology Inc (CGON) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -17.82. The fair price of CG Oncology Inc (CGON) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 42.61 USD , CG Oncology Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：42.61
Fair
Undervalued
-16.36
PE
1Y
3Y
5Y
Trailing
Forward
-12.19
EV/EBITDA
CG Oncology Inc. (CGON) has a current EV/EBITDA of -12.19. The 5-year average EV/EBITDA is -13.81. The thresholds are as follows: Strongly Undervalued below -27.09, Undervalued between -27.09 and -20.45, Fairly Valued between -7.17 and -20.45, Overvalued between -7.17 and -0.54, and Strongly Overvalued above -0.54. The current Forward EV/EBITDA of -12.19 falls within the Historic Trend Line -Fairly Valued range.
-11.61
EV/EBIT
CG Oncology Inc. (CGON) has a current EV/EBIT of -11.61. The 5-year average EV/EBIT is -13.84. The thresholds are as follows: Strongly Undervalued below -27.11, Undervalued between -27.11 and -20.48, Fairly Valued between -7.21 and -20.48, Overvalued between -7.21 and -0.58, and Strongly Overvalued above -0.58. The current Forward EV/EBIT of -11.61 falls within the Historic Trend Line -Fairly Valued range.
3819.10
PS
CG Oncology Inc. (CGON) has a current PS of 3819.10. The 5-year average PS is 3309.14. The thresholds are as follows: Strongly Undervalued below 882.86, Undervalued between 882.86 and 2096.00, Fairly Valued between 4522.29 and 2096.00, Overvalued between 4522.29 and 5735.43, and Strongly Overvalued above 5735.43. The current Forward PS of 3819.10 falls within the Historic Trend Line -Fairly Valued range.
-20.70
P/OCF
CG Oncology Inc. (CGON) has a current P/OCF of -20.70. The 5-year average P/OCF is -12.83. The thresholds are as follows: Strongly Undervalued below -33.22, Undervalued between -33.22 and -23.02, Fairly Valued between -2.64 and -23.02, Overvalued between -2.64 and 7.55, and Strongly Overvalued above 7.55. The current Forward P/OCF of -20.70 falls within the Historic Trend Line -Fairly Valued range.
-16.80
P/FCF
CG Oncology Inc. (CGON) has a current P/FCF of -16.80. The 5-year average P/FCF is -17.83. The thresholds are as follows: Strongly Undervalued below -28.59, Undervalued between -28.59 and -23.21, Fairly Valued between -12.45 and -23.21, Overvalued between -12.45 and -7.07, and Strongly Overvalued above -7.07. The current Forward P/FCF of -16.80 falls within the Historic Trend Line -Fairly Valued range.
CG Oncology Inc (CGON) has a current Price-to-Book (P/B) ratio of 4.85. Compared to its 3-year average P/B ratio of 3.22 , the current P/B ratio is approximately 50.85% higher. Relative to its 5-year average P/B ratio of 3.22, the current P/B ratio is about 50.85% higher. CG Oncology Inc (CGON) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -3.31%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.31% , the current FCF yield is about -100.00% lower.
5.09
P/B
Median3y
3.22
Median5y
3.22
-3.41
FCF Yield
Median3y
-3.31
Median5y
-3.31
Competitors Valuation Multiple
The average P/S ratio for CGON's competitors is 7.32, providing a benchmark for relative valuation. CG Oncology Inc Corp (CGON) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 3774.42%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CGON increased by 55.96% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 43.00K to 1.67M.
The secondary factor is the Margin Expansion, contributed -94.46%to the performance.
Overall, the performance of CGON in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is CG Oncology Inc (CGON) currently overvalued or undervalued?
What is CG Oncology Inc (CGON) fair value?
How does CGON's valuation metrics compare to the industry average?
What is the current P/B ratio for CG Oncology Inc (CGON) as of Dec 05 2025?
What is the current FCF Yield for CG Oncology Inc (CGON) as of Dec 05 2025?
What is the current Forward P/E ratio for CG Oncology Inc (CGON) as of Dec 05 2025?